Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis and Clinical Trials Assessment, 2025 by DelveInsight | Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio

Non-Small-Cell Lung cancer (NSCLC) Pipeline constitutes 100+ key companies continuously working towards developing 120+ Non-Small-Cell Lung cancer (NSCLC) treatment therapies, analyzes DelveInsight.

Non-Small-Cell Lung cancer (NSCLC) Overview:

Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer, originating in the tissues of the lungs. Compared to small cell lung cancer (SCLC), NSCLC typically grows at a slower rate, but it is often already advanced and has spread to other parts of the body by the time it is diagnosed-making early detection and treatment critical. The name "small cell" comes from the appearance of the cancer cells under a microscope, which are small and round. In contrast, the cells in NSCLC are larger. Although NSCLC progresses more slowly than SCLC, it is still commonly diagnosed at a late stage.

Lung cancer affects approximately 230,000 people each year in the United States, and it leads to around 135,000 deaths annually. It accounts for more deaths than prostate, breast, brain, and colorectal cancers combined. Lung cancer is currently the leading cause of cancer-related deaths in men and the second most common in women. However, mortality rates have been declining due to public health initiatives aimed at reducing smoking and tobacco use.

The classification of lung tumors is based on the 2015 guidelines from the World Health Organization (WHO), which utilize immunohistochemistry and light microscopy to guide treatment decisions and predict outcomes. NSCLC encompasses several subtypes of lung cancer, including adenocarcinoma, squamous cell carcinoma, and large cell carcinoma.

Adenocarcinoma is the most frequently diagnosed subtype of NSCLC and makes up about half of all lung cancer cases. Squamous cell carcinoma, which used to be the most common, often begins in the central airways (tracheobronchial tree), although more recent diagnoses are being made in the outer regions of the lungs. Large cell carcinoma is a less common form and is considered a diagnosis of exclusion, meaning it lacks distinguishing features and cannot be classified further through immunohistochemical or electron microscopic analysis.

The causes of NSCLC can be divided into modifiable and non-modifiable risk factors. The most prominent preventable cause is tobacco smoke inhalation. Other contributing factors include alcohol consumption, exposure to secondhand smoke, environmental toxins like asbestos, radon, arsenic, chromium, and nickel, as well as exposure to ionizing radiation and polycyclic aromatic hydrocarbons.

Download our report @ https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

"Non-Small-Cell Lung cancer (NSCLC) Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Non-Small-Cell Lung cancer (NSCLC) Therapeutics Market.

Key Takeaways from the Non-Small-Cell Lung cancer (NSCLC) Pipeline Report

DelveInsight's Non-Small-Cell Lung cancer (NSCLC) pipeline report depicts a robust space with 100+ active players working to develop 120+ pipeline therapies for Non-Small-Cell Lung cancer (NSCLC) treatment.
On February 15, 2024, the FDA granted traditional approval to tepotinib (Tepmetko) for adult patients with metastatic NSCLC harboring mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
In December 2024, the FDA granted accelerated approval to zenocutuzumab (Bizengri) for adults with advanced, unresectable, or metastatic NSCLC harboring neuregulin 1 (NRG1) gene fusions, marking the first approved treatment targeting this specific genetic alteration.
In December 2024, the FDA approved a subcutaneous injectable formulation combining nivolumab and hyaluronidase (Opdivo Qvantig) for use across multiple previously approved adult solid tumor indications, including NSCLC. This formulation offers a more convenient administration method compared to the traditional intravenous infusion.
In August 2024, the FDA approved the combination of amivantamab and lazertinib for patients with advanced NSCLC and specific epidermal growth factor receptor (EGFR) mutations. Clinical trials demonstrated that this combination significantly extended progression-free survival compared to standard treatments.
Key Non-Small-Cell Lung cancer (NSCLC) companies such as Merck Sharp & Dohme LLC, Suzhou Puhe Pharmaceutical Technology Co., LTD, Merus N.V., Zymeworks BC Inc., Cytos Biotechnology, Exelixis, ProfoundBio US Co., Beijing Pearl Biotechnology Limited Liability Company, Pfizer, OncoResponse, Inc., Next Point Therapeutics, Inc., Light Chain Bioscience - Novimmune SA, Medolution Ltd., Immunitas Therapeutics, Shanghai Henlius Biotech, and others are evaluating new drugs for Non-Small-Cell Lung cancer (NSCLC) to improve the treatment landscape.
Promising Non-Small-Cell Lung cancer (NSCLC) pipeline therapies in various stages of development include V940, QL1706, Zenocutuzumab (MCLA-128), ZW49, and others.

Non-Small-Cell Lung cancer (NSCLC) Pipeline Analysis
The Non-Small-Cell Lung cancer (NSCLC) pipeline insights report 2025, provides insights into:
Provides comprehensive insights into key companies developing therapies in the Non-Small-Cell Lung cancer (NSCLC) Market.

Categorizes Non-Small-Cell Lung cancer (NSCLC) therapeutic companies by development stage: early, mid, and late-stage.

Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

Reviews emerging Non-Small-Cell Lung cancer (NSCLC) drugs under development based on:

Stage of development

Non-Small-Cell Lung cancer (NSCLC) Route of administration

Target receptor

Monotherapy vs. combination therapy

Non-Small-Cell Lung cancer (NSCLC) Mechanism of action

Molecular type

Offers detailed analysis of:

Company-to-company and company-academia collaborations

Non-Small-Cell Lung cancer (NSCLC) Licensing agreements

Funding and investment activities supporting future Non-Small-Cell Lung cancer (NSCLC) market advancement.

Request for a sample report @ https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Small-Cell Lung cancer (NSCLC) Emerging Drugs

V940: Merck Sharp & Dohme LLC
QL1706: Qilu Pharmaceutical Co., Ltd.
Zenocutuzumab (MCLA-128): Merus N.V.
ZW49: Zymeworks BC Inc.

Non-Small-Cell Lung cancer (NSCLC) Companies

More than 100 major companies are currently working on developing treatments for Non-Small Cell Lung Cancer (NSCLC). Among them, Merck Sharp & Dohme LLC has a drug candidate that has reached the most advanced stage of development-Phase III clinical trials.

DelveInsight's report covers around 120+ products under different phases of Non-Small-Cell Lung cancer (NSCLC) clinical trials like

Non-Small-Cell Lung cancer (NSCLC) Late stage Therapies (Phase III)
Non-Small-Cell Lung cancer (NSCLC) Mid-stage Therapies (Phase II)
Non-Small-Cell Lung cancer (NSCLC) Early-stage Therapies (Phase I)
Non-Small-Cell Lung cancer (NSCLC) Pre-clinical and Non-Small-Cell Lung cancer (NSCLC) Discovery stage Therapies
Non-Small-Cell Lung cancer (NSCLC) Discontinued & Inactive Therapies

Non-Small-Cell Lung cancer (NSCLC) pipeline report provides the Non-Small-Cell Lung cancer (NSCLC) therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Intravenous
Subcutaneous
Oral
Intramuscular

Non-Small-Cell Lung cancer (NSCLC) Products have been categorized under various Molecule types such as

Monoclonal antibody
Small molecule
Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Non-Small-Cell Lung cancer (NSCLC) Therapies and Key Non-Small-Cell Lung cancer (NSCLC) Companies: Non-Small-Cell Lung cancer (NSCLC) Clinical Trials and recent advancements https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Non-Small-Cell Lung cancer (NSCLC) Pipeline Therapeutic Assessment
• Non-Small-Cell Lung cancer (NSCLC) Assessment by Product Type
• Non-Small-Cell Lung cancer (NSCLC) By Stage
• Non-Small-Cell Lung cancer (NSCLC) Assessment by Route of Administration
• Non-Small-Cell Lung cancer (NSCLC) Assessment by Molecule Type

Download Non-Small-Cell Lung cancer (NSCLC) Sample report to know in detail about the Non-Small-Cell Lung cancer (NSCLC) treatment market @ Non-Small-Cell Lung cancer (NSCLC) Therapeutic Assessment https://www.delveinsight.com/sample-request/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Content

1. Report Introduction
2. Executive Summary
3. Non-Small-Cell Lung cancer (NSCLC) Current Treatment Patterns
4. Non-Small-Cell Lung cancer (NSCLC) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Non-Small-Cell Lung cancer (NSCLC) Late-Stage Products (Phase-III)
7. Non-Small-Cell Lung cancer (NSCLC) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Non-Small-Cell Lung cancer (NSCLC) Discontinued Products
13. Non-Small-Cell Lung cancer (NSCLC) Product Profiles
14. Non-Small-Cell Lung cancer (NSCLC) Key Companies
15. Non-Small-Cell Lung cancer (NSCLC) Key Products
16. Dormant and Discontinued Products
17. Non-Small-Cell Lung cancer (NSCLC) Unmet Needs
18. Non-Small-Cell Lung cancer (NSCLC) Future Perspectives
19. Non-Small-Cell Lung cancer (NSCLC) Analyst Review
20. Appendix
21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Non-Small-Cell Lung cancer (NSCLC) Pipeline Reports Offerings: https://www.delveinsight.com/report-store/non-small-cell-lung-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.